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CHAPTER ONE 
 
GENERAL INTRODUCTION 
 
1.1 INTRODUCTION:  
The burden of disease due to HIV/AIDS (human immunodeficiency 
virus/acquired immunodeficiency syndrome) and tuberculosis (TB) remains 
great for many countries around the world. Continuing attention must be 
devoted to these epidemics if we ever hope to one day contain their 
devastating effects on humankind. An estimated 38.6 million people 
worldwide were living with HIV in 2005. It is estimated that 4.1 million 
people were newly infected with HIV and 2.8 million lost their lives to AIDS 
(1). In the past 25 years, HIV has spread rapidly from a few locations to 
virtually every country in the world, infecting an estimated 65million people 
and killing 25 million worldwide(1). 
HIV/AIDS on its own has created more than 13 million orphans in the world 
with Sub-Saharan Africa (SSA) bearing the greatest burden of the crisis. In 
this region, (which is home to less than 10% of the world’s population) there 
are 25.3 million people with HIV/AIDS, i.e. 70% of all cases globally. In 
2000 there were 3.8 million new HIV infections in sub-Saharan Africa alone 
and 2.4 million people died of HIV/AIDS, representing 80% of all deaths 
attributed to AIDS (2). 
Additionally, SSA carries the greatest burden of HIV-associated TB (3). TB is 
a disease that has caused significant morbidity and mortality to mankind 
throughout history. It is believed to have been around for almost 20,000 yrs 
(4) and, as a rule, has affected the poorest groups of society. Over the years, 
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more devastating forms of the disease have developed (5). In 1999 there were 
estimated to be 8.4 million new cases of TB in the world (6). By 2004, an 
estimated one-third of the global population, around 2,000million people (7), 
was infected with the microorganism, known as Koch’s bacillus. This 
represents the largest reservoir of healthy, infected carriers for any given 
infectious disease (5). 
The WHO report of 2002 declared that HIV fuels the TB epidemic and that 
nearly three-quarters of people infected with both HIV and Mycobacterium 
tuberculosis (MTB) live in SSA (8). It is known that HIV results in the 
reactivation of latent TB, and promotes progression to active TB both in 
people with recently acquired (9) and latent (10) MTB infections. It has been 
estimated in 1997 that global prevalence of MTB infection was 32% (1.86 
billion) (11), whereas 0.18% of the world population (10.7 million people) 
had MTB and HIV co-infection, and 640 000 incident TB cases (8%) had HIV 
infection. The great majority of incident TB cases were found in the South-
east Asian and African countries with the highest overlapping HIV and TB 
epidemiology (12). In 2005, the WHO estimated that 6.5million people living 
in resource-poor countries were in urgent need of antiretroviral treatment ART 
(13). This ever-increasing number will certainly result in more HIV -related 
illnesses, in particular, TB, resulting in greater mortality/negative outcomes. 
The Themba Lethu Clinic (TLC), an ARV rollout site based at Helen Joseph 
Hospital in Johannesburg, Gauteng, currently provides antiretroviral (ARV) 
treatment to about 7000 HIV infected patients. Some of these patients are co-
infected with TB. This study will look at the differences in HIV outcomes 
according to TB status of patients. 
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1.2 Background and Information on Place of Study:  
 
TLC was introduced in 2004 to take care of HIV-infected patients. It functions 
as an HIV clinic providing HAART and is affiliated to the Right to Care and 
the Clinical HIV Research Unit and this to the University of the 
Witwatersrand. TLC is also partnered to the Gauteng Province which ensures 
the sustainability of the clinic.  
TLC is found in the premises of the Helen Joseph Hospital (HJH), in the city 
of Johannesburg, Gauteng province, South Africa.  A Government ARV role 
out center, TLC is considered the flagship of National ARV rollout sites and 
supported by the right to care- the President’s Emergency Plan for AIDS 
Relief (PEPFAR). Situated within a Wits University teaching hospital HJH, it 
serves as a good training site for health students and healthcare workers. TLC 
has strong links to the medical unit of HJH ensuring easy admission for the 10 
to 20 patients per week, needing specialist care (14).  
The clinic is made up of health care workers with more than 10 years 
experience in treating HIV patients. These workers include nurses, doctors, 
laboratory scientists and other auxiliary staff who make up a total number of 
±65persons (14). Three registrars from the hospital, from the medical unit of 
the HJH, work in rotation for 3hours per week carrying out consultations at 
the clinic (14). Approximately 50 HIV tests are conducted a day based on 
clinical analysis and patients requests.  
TLC could count no less than 4300patients by March 23
rd
 of 2006, registering 
30 – 40 patients per week all under 3 basic ARV regimens. By October 2006, 
TLC had registered approximately 6,200 patients on ARV, was initiating 150 
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–200 new patients per month and seeing about 200 patients per day from 
Monday to Thursday (14). Today the clinic can boast of a staggering no less 
than 8000patients in their data base. 
Enrollment into the programme follows the National ARV Rollout guidelines, 
which in turn follows WHO recommendations in providing ARV (this states 
that clinical Stage 4 disease or those with CD4 count less than 200 are 
initiated on HAART) (15). 
With its primary aim the care of HIV patients, TLC has a good system of 
capturing patient information. Patient information/Data at the TLC is stored on 
TherapyEdge-HIV™  which is an interactive data base. This provides a good 
opportunity for research and analysis.  
This study will analyze three years’ worth of data/information from April 
2004 to April 2007 of the TherapyEdge-HIV™ data base for patients on 
HAART at TLC who meet the inclusion criteria. 
 
    1.3    Problem Statement:  
HIV/AIDS and TB are two of the world’s major pandemics, with most of their 
effects felt in sub-Saharan Africa. In trying to control these pandemics, efforts 
have been largely aimed at prevention with little attention given to care (2). 
Treatment of patients with both HIV/AIDS and TB is a major challenge in the 
care and control of HIV/AIDS. The ever increasing numbers infected with 
both diseases, makes it imperative for health scientists and researchers to 
redefine their position and goals in combating these diseases. The global 
burden of TB remains enormous because there are insufficient TB control 
programmes and higher rates of TB and HIV co-infection (12). 
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The WHO’s ‘3 by 5’ initiative has stirred up many developing countries to 
make antiretroviral therapy available to their HIV infected patients (16).  This 
development raises questions about when it is appropriate to start ARV 
therapy in those dually infected with HIV/AIDS and TB, the difference in 
effect of ARV therapy between those only infected with HIV and those dually 
infected with HIV and TB is also unclear and requires careful research. 
With so much literature available universally on HIV and TB, how they 
interact and inter-relate, very little literature can be ascertain to be available 
for the differences in outcome in ARVs in HIV patients with TB and those 
without TB. A major reason for such limited literature could be that, ARVs in 
most African countries have only recently become available. The issue of 
ARVs is generally new in most African societies or at least not that old and so 
too is information and data on such a population/ patients. Studies on the 
action of ARV drugs, its outcome in HIV-TB positives and HIV-TB negatives 
must consider the fact that while a substantial burden of the dual infection of 
HIV and TB is also experienced by children, the majority of the burden is 
borne by adults (17). 
       Research Question: What are the differences in HIV/AIDS outcomes 
comparing adult HIV infected patients of the TLC with and without TB, who 
have at least 1 follow up clinical visit post initiation in the period April 2004 
to April 2007? 
    1.4    Justification/ motivation:  
Keeping in mind that HIV/AIDS increases the incidence of TB, when you 
consider the estimates of June 2005 that 6.5 million people living in resource-
limited settings were in urgent need of ARVs (13), and that other estimates in 
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2004 showed populations in the developing world account for 95% of all 
cases of HIV-infection, more than 99% of HIV-related deaths, about 95% of 
all TB cases, and about 98% of TB-related deaths (18) it becomes clear that 
more has to be done in both research and care actions. 
Despite adequate antituberculous therapy, many individuals co-infected with 
TB and HIV have an accelerated course of HIV disease and shortened survival 
(19). The introduction of HAART has greatly increased the survival 
probability of HIV patients and decreased the probability of opportunistic 
infections in these patients (20). The same is expected of TB infected HIV 
patients but the problem here is the potential for complex drug interactions, 
overlapping adverse reactions, noncompliance due to the pill burden of 
multidrug therapy, and drug malabsorbtion (21). Thus the introduction and 
adequate follow up of such persons may be of utmost importance as to timing, 
urgency and survival of these patients.  
The availability of data and the fact that one could show an aspect of the 
provision of ARV that could impact on its provision and action provides 
motivation for the completion of the study.  
 
 1.5 OBJECTIVES 
      1.51   General Objective: 
To evaluate and compare cohort treatment outcomes of HIV infected TB 
patients and HIV infected non-TB patients treated with HAART at baseline, 
3-month, 6-month and 12-month intervals at the TLC between April 2004 and 
April 2007. 
      1.52   Specific Objectives: 
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- To measure and identify differences in the following outcomes: CD4 
gain, undetectable viral load, death, loss to follow up and  weight gain 
in HIV patients on HAART at the TLC at baseline, three months, six 
months and twelve months after initiation of HAART in the period of 
April 2004 to April 2007. 
- To measure the effect of confounders on outcomes of ARV/HAART in 
TB+ and non-TB patients with at least one follow up visit in the period 
April 2004 to April 2007 at the TLC. 
- To show regression, repeated measure and survival analysis of 
endpoints in TB+ and TB- patients of the TLC. 
 
1.6 Literature review:   
Introduction and Effect of HIV and TB 
TB although known for more than thousands of years (>6,000 years) now, has 
had its control and eradication only becoming possible after the introduction 
of multi-drug chemotherapy in the 20th century (22). The number of cases of 
TB has increased exponentially worldwide during the last two decades. This 
has in part been accredited to the HIV pandemics, since HIV coinfection 
significantly changes the natural balance between man and the Koch bacillus 
(23, 24). 
TB kills 2 million people every year globally. It was declared by WHO in 
1993 “a global emergency” (25). The global epidemic is growing and 
becoming more dangerous. The emergence of multidrug resistant TB (MDR-
TB) and extreme drug resistant (XDR-TB), and the spread of HIV are 
contributing to the worsening impact of the disease (26).  
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    Other Related Studies 
Few studies have so far been carried out in places like the UK, Thailand, 
Taiwan and Malawi, trying to show differing outcomes of ARV/HAART 
between TB+ patients and TB- patients. Generally most of these studies have 
used cohort designs. In Sub-Saharan Africa, up to early 2007 to the best of my 
knowledge there was no such study comparing outcomes of TB and non TB 
HIV patients in the post ARV era. The studies in Malawi seem to be the first 
around this region and this research should be the first of its kind in South 
Africa. 
In principle, HIV-positive TB patients should benefit from ART, which leads 
to a reduction in HIV-related mortality and HIV-related recurrence of TB 
disease. So too in principle should HIV-positive non TB patients show better 
out comes when put on ARVs since they are on a single type of treatment and 
as such should present with better respond and adherence.  
Two studies carried out in Malawi tried to compare outcomes of ART on 
patients who had TB and those that did not have TB. The first of this studies 
was more or less a general one considering data/information registered in the 
ART master cards and ART registers of patients who have been initiated into 
the ARV role out scheme of the country. Between 2004 and prior to the 
carrying out of the research, health facilities in Malawi were gradually 
becoming accredited and starting ART delivery services, and by March 2006, 
66 sites were accredited and were delivering ART using the national 
standardized systems. Using a retrospective cohort study design Makombe, 
Haies et al selected a sample of 6967 non TB HIV patients and 938 HIV with 
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TB patients (total sample of 7905) and compared their 6months cohort 
outcomes. 
This Malawi study (16) showed that HIV/AIDS patients with TB had a slight 
bigger proportion with better outcomes than those without TB. The study 
showed that a greater proportion of HIV/AIDS patients without TB died, 
defaulted or stopped treatment or were transferred when compared with 
patients with TB. Approximately 75% of HIV-positive TB patients were alive 
and on ART 6–12 months after starting ART compared to 71.5% for HIV-
patients without TB. And if we had to consider that patients who were 
transferred or stop treatment were still alive at the 12
th
 month, then the 
proportion of HIV-positive TB patients who are alive at 6 and 12 months after 
starting ART would increase to approximately 80% as opposed to 78% for 
HIV-positive non TB patients. 
 This findings are in line with statements from Okwera et al. (27) who 
reported that cure rates are higher among HIV-infected TB patients while 
death (28; 29) and recurrence rates are lower (30; 31) with rifampicin 
containing than with non-rifampicin-containing regimens. Controversially, 
malabsorption of rifampicin and isoniazid has been reported in HIV-infected 
TB patients, resulting in reduced drug concentrations in tissues and blood and 
possibly worse treatment outcomes (32). 
A second study carried out just along side the above in Malawi tried to 
compare such outcomes of ARV among children, (17). This study was aimed 
to determine outcomes of HIV-infected children at Mzulu Central Hospital, 
North Malawi who were started on antiretroviral therapy (ART) because of 
either active TB or a past history of TB within the two years prior to the 
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research and comparing them to those children with HIV but no history of 
present or past TB. This study showed no clear difference in outcomes in HIV 
infected children with or without TB and in fact, suggested that good 
outcomes are potentially achievable in HIV infected children on HAART both 
with TB and without TB. This study compared outcomes for children less than 
14years of age at 6-month and at 12-month by using survival probability. It 
was noticed that at 6-month, survival probabilities for the groups though not 
the same were very close and high. The 6-month probability of survival was 
0.86 for children with active TB, 0.94 for children with a past history of TB 
and 0.89 for children with a non-TB diagnosis. At 12 months the 
corresponding probability of survival was 0.86 for children with active TB, 
0.86 for children with a past history of TB and 0.88 for children with a non-
TB diagnosis. There was no significant difference in the outcomes for the 
three groups up to 12 months (log-rank test, P _ 0.59) (17). This study is in 
some way contradictory to the one by Makombe et al (16) which suggested 
better outcomes in HIV-TB patients than HIV-non TB patients. In this study 
comparing outcomes in children by Bong, Chen et al (17), there is no clear 
difference amongst the groups. Being the first and only available such study 
on children in Sub-Saharan Africa, the repeatability of this results cannot be 
ascertained but the same results have been shown by studies undertaken 
involving adults in other parts of the world. 
The study comparing out comes of HIV/HAART in children (<14years of 
age) in Malawi is in line with a study carried out in 2003 by Hung, Chen, 
Hsiao et al in Taiwan (12). This study was structured to demonstrate the 
impact of ART on outcomes of HIV-infected TB patients in a consecutive 
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cohort of 716 HIV-infected patients receiving medical care from June 1994 to 
June 2002 at a University Hospital there in Taiwan (12). Using various 
statistical models, determining survival probabilities and adjusting for age, 
sex, year TB diagnosis or enrollement, baseline CD4 cell count, and presence 
of concurrent AIDS-associated illness at TB diagnosis or enrollment, use of 
ART, and type of ART (HAART versus two NRTIs versus no antiretroviral 
therapy) the study showed differences in crude mortality rates of 14.31 per 
100 person-years for TB-infected patients and 9.98 per person-years for the 
non-TB patients but showed similar risk of death among the two groups. The 
adjusted hazard ratio of the two groups of patients was 1.05 (95% CI, 0.73 – 
1.49) and was similar in the two groups before and after the introduction of 
HAART. This hazard ratio was 1.18 (0.65, 2.14) before HAART and 0.89 
(0.57, 1.69) after HAART for both groups of patients showing their similar 
outcomes of survival and death (12). 
Research carried out in London by Keertan Dheda, et al (33) comparing 
outcomes of HIV-TB infected patients before and after the introduction of 
HAART shows a mark improvement in survival of patients infected by both 
TB and HIV. Comparing outcomes in patients starting TB treatment during 
the pre-HAART era (before 1996) with those patients starting treatment 
during the HAART era (during or after 1996) they came out with results that 
showed that HAART substantially reduces new AIDS events and death in co-
infected patients. Those with a CD4+ cell count !100 cells/mm3 have a high 
event risk during the intensive phase of anti-TB treatment as such 
recommended that such results should be taken into account when deciding to 
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delay HAART in co-infected patients with CD4+ cell counts !100 cells/mm3 
because it could be a very vital aspect of their survival (33). 
Looking at the limited available literature on this subject, it becomes clear that 
one cannot confidently declare what the outcomes are like comparing HIV-
infected TB patients and HIV- non infected TB patients. Studies carried out 
pre ARV/HAART era all showed very negative results in the out comes of 
patients treated/cared for with co-infection of HIV and TB. Many studies in 
South Africa and the world that look at outcomes of HIV co-infection with TB 
pre ARV era were done studying pregnant women or maternal mortality data. 
One of such studies carried out in South Africa in 2001 studying maternal 
mortality associated with TB and HIV-1 co-infection by M. Khana, et al, 
came out with staggering mortality rates/ death rates (34). Of a total of 50 518 
deliveries, 101 maternal deaths were recorded. Of these deaths, 29.7% 
(30/101) were HIV-1 infected. The overall mortality rate was 200/100 000; for 
HIV-1-infected women this was 323.3/100 000, HIV-1-negative mothers, 
148.6/100 000 live births. The attributable fraction of overall deaths as a result 
of HIV-1 was 15.9%. Fourteen of the 15 mothers with tuberculosis were HIV-
1 co-infected. The mortality rate for tuberculosis and HIV-1 co-infection was 
121.7/1000; for tuberculosis without HIV-1 co-infection, mortality was 
38.5/1000 (34). This study in South Africa was in line with many other studies 
carried out in Africa before 2004 (before the introduction of ARVs by most 
countries) showing negative outcomes of HIV and TB co-infection going long 
ways to strengthen the notion that HIV combined with TB in an absence of 
ARV has more devastating effects. This is understandably and clearly seen 
when the clinical issues related with coinfection are studied. That is knowing 
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the precise problem of drug interaction, pathogenesis and immune 
reconstitution in HIV, TB coinfection. In an ARV era, comparing patients 
with those that are just HIV positive but free of TB. 
    Clinical Issues of HIV, TB and coinfection 
TB and HIV infection have important and bidirectional interactions that 
impact on the epidemiology, natural history, clinical presentation, and 
management of each pathogen. (35) 
Following successful transmission of HIV from one individual to another, the 
course of subsequent infection is quite variable and dependent on a number of 
factors. These factors include characteristics unique to the virus itself as well 
as a variety of cellular immune responses and other features of the host.(36) 
Acute or primary HIV infection (PHI) is followed by a variable period of time 
during which viral replication persists and an inexorable progressive 
immunologic decline results. Throughout most of this period, the patient may 
be entirely asymptomatic. However, the end result of consequent 
immunologic deterioration is a state of profound immune suppression that 
renders the infected individual susceptible to a multitude of opportunistic 
infections and malignancies (36). The degree of viral replication at this stage 
is the prime determinant of time necessary to progress from HIV infection to 
AIDS. Potential symptoms of HIV infection include fever, fatigue, headache, 
diarrhea, nausea and vomiting, weight loss, neurologic symptoms, sore throat, 
myalgias, arthralgias, night sweats and signs like Lymphadenopathy, 
Pharyngitis, with or without exudates, rash usually maculopapular, thrush, 
Hepatosplenomegaly, Oral ulcers and Genital ulcers (36). Initiation of ARV in 
HIV infected persons is generally influenced by the CD4 count that decreases 
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with stage, level of HIV/AIDS and some opportunistic infections. With the 
knowledge that TB could also cause CD4 to reduce, the problem of actually 
determining the unset of ARV in co infection patients is highlighted. 
Classic pulmonary TB, with upper-lobe infiltrates and cavitary lesions, may 
occur in HIV-infected persons with relatively intact immunity. As CD4 cell 
counts decrease, TB is more likely to manifest atypically in the chest (without 
cavitary disease, or with lower-lobe disease, adenopathy, pleural effusions, or 
interstitial or miliary infiltrates), as extra-pulmonary disease.(37). 
 Tubercle bacilli incite an inflammatory response  known as granulomatous 
inflammation Cell-mediated immunity and hypersensitivity reactions 
contribute to TB infection (38). TB bacilli enter the alveoli and are   
surrounded and engulfed by macrophages. Followed by the development of 
single, circumscribed granulomatous lesion called Ghon’s focus (TB bacilli, 
modified macrophages, and other immune cells) (38). Ghon’s focus undergoes 
necrosis within 2 to 3 weeks. This occurs at about the time that the tuberculin 
test becomes positive, suggesting that the necrosis is caused by the cell-
mediated hypersensitivity immune response. At the same time, tubercle bacilli 
drain along the lymph channels to the tracheobronchial lymph nodes of 
affected lung causing caseous granuloma (38). First-line TB drugs identified 
include; Isoniazid, Rifampin, Rifabutin, Rifapentine, Pyrazinamide, 
Ethambutol and Second-line drugs; Cycloserine, Ethionamide, Streptomycin, 
Amikacin/kanamycin, Capreomycin, P-Amniosalicylic acid, Levofloxacin, 
Moxifloxacin, Gatifloxacin (38). With the amount and type of medication that 
is taken as anti TB, co infection registers another crisis of potential over 
medication and possible drug interactions when ARV is considered. Apart 
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from these considerations, there are reasons to avoid initiating antiretroviral 
therapy in patients with active TB, including avoidance of potential drug 
interactions and toxicities and avoidance of the “paradoxical response” or 
“immune reconstitution inflammatory syndrome” to anti-TB therapy that can 
be caused by immune reconstitution under antiretroviral therapy. This 
response, which has been observed soon after initiation of antiretroviral 
therapy, is characterized by persistent or increasing fever, severe pulmonary 
inflammation, and lymphadenopathy (14). But it has also been noticed the 
number of deaths that can be prevented when ARVs are commenced early in 
HIV/AIDS patients (CD4 counts < 200) whether with or with out TB. 
A biologic synergy exists between these infections and treatment: HIV-
induced immunosuppression increases susceptibility to TB infection, and 
active TB infection enhances HIV replication through immunologic 
stimulation. The populations infected by these 2 pathogens overlap in many 
respects, creating epidemiologic synergy (37). Therefore actively caring and 
providing better wats to care for the two conditions is vital and until proven 
other wise most be done simultaneously. Trying to ascertain best possible 
period and differences that exist in outcome as a result of time when ARV was 
introduced is and shall play a very important role in going through this 
dilemma. Research and clinical studies that look into these aspects of HIV and 
TB need to be multiplied and supported. Recent guideline for treatment of co 
infection is; when not eligible for ART treat TB, when eligible for ART but 
CD4 > 200, treat TB first and defer initiation of ART until rifampin-
containing regimen completes. But when eligible for ART and CD4 <200, 
treat TB and HIV at the same time (39). 
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CHAPTER 2 
METHODOLOGY 
      2.1 STUDY DESIGN:   
The study is a prospective cohort study. Data on patients on HAART at the 
TLC (At Helen Joseph Hospital) who have at least 1 follow up clinic visit in 
the period April 2004 to April 2007 is to be analyzed. Analysis will involve 
regression, survival and repeated measures analysis. 
    2.1.1 ABOUT THE TLC COHORT AND DESIGN OF THE COHORT 
        Started in April 2004 with the government role out date, the Themba 
Lethu Clinical cohort has been growing ever since. Today, TLC shows more 
than 9000 patients. These patients are followed up for ARV compliance and 
adherence, changes in HIV state, opportunistic infections and wellness 
programmes. The cohort is not designed particularly for research purposes, it 
is designed for the care of patients but since data/information that is collected 
from patients is well organized, managed and stored it serves as a good 
material for research and analysis. Information/data in TLC is collected 
systematically, prospectively and continually. A patient after initiation and 
first laboratory test will follow a monthly programme of re-visit to the clinic 
for collection of ARVs and weight verification. At certain months during 
these monthly visits, patients will carry out test like CD4 counts, viral load 
examinations, hemoglobin counts, liver function tests, subjective opportunistic 
infection test amongst others. 
Data/information that are stored on patients are collected using consultation 
forms, laboratory request and results forms, nurses clerking forms and also 
directly in a computer data base designed to enter patient information the 
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TherapyEdge-HIV™. Information on patients is confidential and visited by 
only designated staff members of the clinic and the Clinical HIV Research 
Unit CHRU. 
The TLC cohort receives and follows up patients from any location of the 
country. It involves a variety of race even thought the black race is far more 
dominant. It cares for men and women, adults and children. Enrollment into 
the role out and programme for patients doesn’t demand any specific 
requirements but for HIV sero-positivity. 
 
    2.1.2 STUDY POPULATION: 
The study is a retrospective analysis of a cohort of appxoximately 6,000 
patients who met the inclusion criteria and  enrolled at the Themba Lethu 
Clinic between 31 April 2004 and February 2007. After data cleaning an 
estimated 5500 patients over the age of 18 years are expected to be available 
for analysis.  
.  
   2.1.3 QUESTIONNAIRE DESIGN 
Apart from the forms (consultation, laboratory request and results forms) 
filled at initiation and at consultations, a computer based questionnaire is used 
to fill in required information obtained from patients either at consultation, 
ARV collection visits and from laboratory examinations. It is a four page 
TherapyEdge-HIV™ questionnaire that can be easily printed from the 
TherapyEdge-HIV™ data entry programme. It includes payment requisition 
forms and follow-up visit forms which are easily and directly linked with 
previously collected data in the data base using patient unique identifiers like 
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file id, pool id or id_patients. This computer base data entry form is in English 
and serves all purposes of data collection and entry at TLC. 
 
  2.1.4 WORK AT CLINIC/ FIELD WORK 
Data/information on patients at the clinic is collected by an average of 60 
trained health personnel; doctors, nurses, pharmacists and pharmacy 
attendants by means of consultations and laboratory test. Data used for this 
study will be information collect on patients between April 2004 and April 
2007. Such information are collected each working week day where by 
patients come in for initiation, ARV collection and laboratory test. Data 
collection is systematic, continuous and repeated for each patient post 
initiation. 
 2.1.5 DATA PROCESSING 
Data used for the study is information obtained from initiation, consultations 
and observations conducted during routine visits of patients for ARV on roll 
outs at the TLC. The data collection tools used here are basically patient’s 
clinic files/forms filled by nurses and doctors. These information, are entered 
almost immediately into the TherapyEdge-HIV™ data management 
programme using the built in questionnaire. Information and data are also 
obtained from routine physical and laboratory examinations carried out on 
these patients when they come in at particular visits. From the TherapyEdge-
HIV™, data is later transferred and managed using the SAS software package. 
Data entries are done by the personnel of the clinic. All data obtained is stored 
as a computerized data set and backed up in documents. These are only 
consulted by authorized personnel. Information/data on patients for this 
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research are management and obtained from the epidemiologist/data manager 
of the CHRU at the TLC-Helen Joseph Hospital. 
The collection of the various variables is not simultaneous. Weight is 
collected every visit as patients come in for ARV clinical visits. CD4 counts 
are carried out at baseline (day of initiation of treatment), 4
th
 month, 10
th
 
month visits and each subsequent 6months visit. Viral load is done at 4months 
after starting ARV and repeated at intervals as for the CD4.  
All demographic and socioeconomic variables are entered in the form filled 
by patients at initiation visit. 
 
2.1.6 QUALITY CONTROL 
Information/data on patients of the TLC is constantly controlled for its quality. 
The data manager in place constantly checks and manages data. For the 
purpose of this research, most variables which where thought of as partially or 
poorly collected, where left out at analysis. Having information stored in 
patient files gives room of a recheck to make sure that an entry was rightly 
done. 
     2.3 STUDY SUBJECTS:  
Patients’ information/data from clinic (TLC) visits and examinations are 
studied for potential outcome differences in HIV infected patients with TB 
(HIV+TB+) compared to HIV infected patients without TB (HIV+TB-). In 
this study, There are actually 4 groups of patients: (i) those who never had 
TB; (ii) those with TB at ARV initiation + history of past TB; (iii) those with 
TB at ARV initiation + no history of past TB; (iv) those with no TB at ARV 
initiation + history of past TB [Another group which we shall not talk about in 
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this study are those that get TB while on ARV (either early or late)].  We will 
basically compare ii and iii (test group) against i and iv (control). 
- Inclusion Criteria: 
        - All study participants must be patients enrolled for ARV rollout or care 
at the TLC. 
        - Patients must have at least 1 follow up clinic visit after initiation, and 
must have been enrolled at clinic between 1
st
 April 2004 and 1
st
 April 2007 
and are on regimen 1A which is the friendly most common regimen. 
        - All patients must be of age 18 and above. 
        - All patients must be on HAART, specifically, regimen 1A at initiation.  
- Exclusion Criteria:  
        - Any person with no follow up post initiation. 
        - Patients below 18years of age. 
        - Any person not on ARV or treatment regimen other than regimen 1A at 
initiation. 
     2.4 KEY WORDS: 
- TB positive (TB+): All those on treatment for tuberculosis 
(Mycobacterium tuberculosis) at the time of ARV initiation whether 
diagnosed by laboratory examination or on clinical grounds. 
- TB negative (TB-): All those without a current diagnosis of 
tuberculosis (No M. tuberculosis).                                      
- HIV/AIDS Patient: Infected with HIV (40). AIDS is when an HIV 
patient has a CD4 count less than 200 (41) and is infected/ becomes 
sick from opportunistic infections. 
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- HIV/HAART End Points (outcomes): Terminal or gateway. Those 
variables compared to determine differences among the various groups 
of patients, HIV+TB+ and HIV+TB-. 
      -   ARV regimen 1A: Regimen 1A is a combination of ARVs (lamivudine, 
stavudine and efavirenz) given to HIV infected patients with CD4 counts 
below 200 as laid down in the CCMT guidelines. (42). 
      -   Case of TB: The study considered every individual/patient on ARV 
regimen 1A at the Themba Lethu clinic who has been diagnosed with TB and 
was with TB/TB medication during the start of ARV. 
 2.5 VARIABLES OF INTEREST (Exposure & Outcome Variables): 
         2.5.1 EXPOSURE/ EXPLANATORY VARIABLES 
Variables the study will use are those available in the data base. These 
variables include demographics, clinical investigations, laboratory 
examinations, and socioeconomic status. 
a. Demographic and Socioeconomic Status. 
- Age of patient 
- Ethnicity/Race 
- Gender and employment status 
b. Clinical Investigations 
-     Visits to clinic 
- Weight  
c. Laboratory examinations 
- CD4 Counts 
- Viral Loads 
- Hemoglobin levels 
- TB status and liver function. 
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           2.5.2 OUTCOME VARIABLES:  
       HAART/ARV endpoints/ out come variables will include:  
- Viral load: Detectable or undetectable from laboratory 
examinations. 
- CD4 count: Determined from laboratory investigations at 
baseline, 4-6months and at 10-12months to determine an 
increase or decrease in counts. 
- Weight: This was measured to determine weight gains or 
loss as a result of 
       continuous treatment. Measurement was done monthly. 
- Hemoglobin counts/level: Carried out by laboratory 
examinations to check for changes in blood counts. 
Measurement here will be considered at base and 1month. 
- Died/loss to follow up: at any stage post start of ARV 
therapy (1, 3, 6, 9 & 12month). 
- Liver function: Laboratory test will help in indicating 
adherence to medications. 
 
      2.6 HYPOTHESIS:   
Anti tuberculosis medication has negative effects on the effectiveness and 
outcome of highly active antiretroviral therapy in HIV/AIDS patients. 
2.7 Scope and Limitations. 
As a prospective and secondary data analysis study, the investigation has a 
number of limitations. These are listed below; 
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  a). The use of already collected data in itself meant that the researcher could 
not manipulate or amend any variable or collection tool. The researcher has to 
use what is available to him. 
  b). Some variables which could act as potential confounders like occupation/ 
wealth index are not examined due to their absence in the data set. Other 
variables in the data set could not be used because of partiality at collection 
phase. 
  c). As analysis is restricted to information/data on data set, biases such as 
measurement bias, recall biases which are more probably a concern to the 
study are not considered in analysis or  in data cleaning. 
   This study relies on data captured at the clinic on TherapyEdge-HIV™. 
Some of this information does not match with the patient and some are 
incomplete. Even thought these draw backs exist, in all, TherapyEdge-HIV™ 
has greatly improved on data capture time and the follow up of patients. It has 
also improved data output and the transfer (export) of data to SAS. In all, the 
fact that data was readily available made it possible and realistic to carry out 
such a research. 
 
2.8 PLANS FOR THE DISSEMINATION OF RESULTS 
This study on approval and completion will be made available to the TLC, 
suggestions on how to improve on data and patients care will be addressed. 
Also the study will be made available for educational and research purposes 
for students and others who could need information. A plan for a poster or a 
publication is envisaged in order to keep the information as widely available 
as possible. 
                                                                                                                                                        25
2.9 ETHICAL CONSIDERATIONS 
Secondary data collected from patients on ARV treatment at the TLC will be 
analyzed in this study. Data is obtained already de-identifiable (coded) and as 
a computerized data set. Before obtaining the data from TLC, a form of the 
Standard Operating Procedure, norms and principles was read and signed by 
the student researcher declaring to keep data/information confidential and will 
be used for the sole purpose for which it was granted. This signed document 
acts as a prerequisite to obtaining information (data) and is also needed for 
TLC to provide a consent/go ahead for the data to be used for a study. 
Study was ascertained to be in line with principles of non-maleficence, 
beneficence, and autonomy. 
Ethical approval was obtained from the University of the Witwatersrand 
Ethical Committee. 
2.10 DATA MANAGEMENT 
Permission to use the Themba Lethu Clinical cohort data was obtained from 
the Helen Joseph Hospital according to protocol. That is an ethical clearance 
was first obtained for the study before authorization to use data could be 
granted. The data was downloaded from the TherapyEdge-HIV™ information 
software into SAS. This was done by the epidemiologist and data manager of 
the Themba Lethu Clinic/ CHRU. The imported data in SAS was de-
identifiable. The data was checked for the complete collection of some 
variables and was then stored in five separate CSV datasheets (demographics, 
doctors visits, laboratory, conditions and pharmacy visits). 
Further data management, cleaning and recoding was done using the statistical 
software package STATA 9.1 by importing and linking the CSV files in this 
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software package. A total of 52 variables were imported into STATA 
including variables mentioned in section 2.5.1 and 2.5.2 and other variables 
necessary to create them or necessary for multivariate analysis. Other 
variables created for survival analysis purposes included; treatment outcome 
which denotes those who defaulted and those who are continuing their ARV 
medications, BMI gain which shows success (a gain of more than 1uniy of 
BMI) and failure (anything less than 1unit BMI gain), weight gain with failure 
being any gain of 2kg (which is actually a positive outcome). Other variables 
include CD4good which was a failure when an individual/patients CD4 rose to 
greater than 200, astgood and altgood which were variables created to model 
survival analysis of the incidence and failures of liver function test (above 40 
being failures), viral good which was a success (failure) when a patients viral 
load counts dropped to below 400. The last variable created purposely for 
survival and repeated data analysis was hbgood which showed failure 
(clinically positive) as when a patient registered a positive change in 
hemoglobin counts. The number of observations at this stage varied 
depending on the variables but was for a total number of 5818 HIV patients on 
ARV. These numbers of patients represent all the adults above 18years of age 
who were enrolled between the 1
st
 of April 2004 and the 1
st
 of April 2007 and 
who are regimen 1A of ARVs at the Themba Lethu Clinic. 
A total of more than 3000 patients were excluded either because they were 
under 18years of age, not on regimen 1A, had no age attached to their 
observations or were not on ARVs. Some variables that were planned to be 
analyzed were dropped due to incompleteness in collection and very poor 
response. Employment status/profession was dropped because it was noticed 
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from investigations that most of the patients did not report their true 
employment status in fear of not being treated for free or at a lower cost. 
Generally the data was made usable in STATA and the variables used 
altogether had a response rate and or completion of more than 90%. 
 
2.11 DATA ANALYSIS 
Data set obtained from the TLC in SAS format was analyzed in STATA a 
conversion that passed through CSV data format. This conversion was done 
due to the researchers experience and knowledge in working with STATA. 
Some continuous variables were categorized prior to analysis in order to ease 
the analysis process. These variables include: age at enrollment into the TLC 
ARV roll-out programme was categorized into five groups, all those18 and 
more but less than or equal to 25 fell in the first category 18 – 25, all those 
greater than 25 but less than or equal to 35 are in the group 26 – 35. Those in 
the group 36 – 45 were more than 35years old but less than or equal to 45, the 
group 46 – 55 was made up of those greater than 45 years of age  but less than 
or equal to 55 and the last group those older than 55 years (>55). Ethnic group 
like other variables was re-categorized into four groups; Blacks, Asian, 
coloured and white. This was done by combining certain response that showed 
to be close or same. Other variables like Conditions were generated from 
infections and then re- categorized into either having TB or not (0 = TB & 1 = 
NonTB). The outcome condition dead was categorized into either Yes for 
someone who died and No for any individual still alive. A new variable was 
also created to use in analysis known as tbgroup. This variable shows the 
interval when individuals were reported of having TB that is before, during 
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(had TB before the start of ARV and recovered after ARV onset) or after the 
start of ARVs and those who never had TB. Another variable arvstatus shows 
three potential outcomes; defaulters, loss to follow up and those still adhering 
to their drugs. From arvstatus, loss to follow up was created to comprise of all 
defaulters and those loss to follow up. At TLC, patients are called ‘defaulters’ 
if they have failed to keep an appointment within a month and ‘lost to follow 
up’ after three months. Such patients are actively traced by telephone and 
home visits but many remain untraceable. It is generally believed that most of 
the defaulters and those loss to follow up either were receiving treatment in 
other health centers or were dead. Generally, the mean follow up time for all 
those lost to follow up was about 248days while the total mean follow up of 
all patients was 422.5days. All laboratory outcomes; CD4 counts, viral load, 
HB, AST, ALT were maintained and analyzed as continuous variables. These 
variables were cleaned by removing extreme observations. Variables like 
weight was measured in kg and cleaned while height was measured in 
centimeters after some cleaning had been done. A variable for BMI (bmi) was 
generated to actually see and differentiate the changes in body mass index 
over time in our two groups of patients. At this stage most of the non-required 
variables from the original data set were dropped and each data set was left to 
contain demographics and the important variables of the category.  
Analysis carried out using already collected computerized data from the TLC 
was done in three levels. Data analysis involved all eligible HIV infected 
patients on ARV therapy at the TLC from April 2004 to April 2007.  
The three levels of data analysis started with descriptive data analysis which 
was carried out describing the distribution of CD4 counts at base, 3 months, 
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6months and 12months, viral loads, weight, BMI, liver function (AST & 
ALT) and hemoglobin levels, describing any differences among patients who 
had TB and those without TB/ who have never had TB. At this stage results 
are shown as frequencies, means, proportions and standard deviations. These 
results are shown in tables and graphs histograms and pie charts. 
At the Second level of analysis, univariate and bivariate analysis was carried 
out, trying to ascertain relationships between any of the explanatory variables 
and the outcome variables. Cross tabulations, Relative risk, p values, and 
confidence intervals and associated chi-square values are shown as necessary. 
In the third level of analysis, Linear Regressions and multivariate analysis was 
done to quantify relationships and show estimated changes over time. At this 
stage, survival and repeated measures analysis was also carried out and results 
are shown in tables, graphs and plots for curves. Through out the analysis 
process, to see and show the effect of the duration and or time a patient had 
TB, most models were modeled to take into consideration the tbgroup. At 
other points differences are ascertained by gender and age group. 
Assumptions were checked by using histograms, and other parameters to 
acknowledge distribution of results. 
After all analysis was carried out, a comparison between the different groups 
of HIV patients was done to show, see and outline differences in the outcomes 
of HAART among TB patients and non-TB patients. 
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CHAPTER THREE 
RESULTS 
3.1 CHARACTERISTICS OF COHORT PARTICIPANTS 
The study had as main objective to show and evaluate the differences in 
outcomes and ARV response in patients of two different groups that is, those 
HIV patients who at a point in time presented with TB against those who have 
never had TB. With age considered at 18 years and above and regimen 1a 
considered as ARV therapy of choice, the study cohort had 5818 participants, 
36.04% of which were males (2,097) and 63.96% females (3,721). There was 
a general average of 422.51 days of follow up while those lost to follow up 
had in average 248 days of follow up. This chapter shall actually try to 
statistically determine such differences in TB and non TB patients. This shall 
be done by carrying out several statistical models. As regarding the 
distribution of TB and Non TB patients, it was noticed that 19.23% (1,048) of 
the patients had been diagnosed with TB at some point in time while 80.77% 
(4,770) had never been diagnosed with TB. Figure 3.1 shows a pie chart of the 
distribution of patients followed up at TLC between 01
st
 April 2004 and 01
st
 
April 2007 by gender. 
63.96%
36.04%
Female Male
Distribution of Patients followed up by Gender
 
Fig 3.1: Percentage distribution of Patients by Gender 
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By April 1
st
 2007, a total number of 269 (4.62%) patients had been reported 
dead from the cohort and a further 1,278 (21.99%) had stopped receiving 
ARV (loss to follow up). With the assumption that any other person was still 
alive, the study had more than 73% of its participants surviving to the 
censoring date of April 1
st
 2007. Figure 3.2 below shows distribution of deaths 
among the two groups of patients, where 4.96% of all TB patients are shown 
to have died while death amongst those who never had TB was 4.32%. 
4.962%
95.04%
4.316%
95.68%
TB NON TB
Proportion of Dead by TB Status Proportion of Dead by TB Status
YES NO
Graphs by condition
Distribution by Patient Condition
 
Fig 3.2: percentage distribution of deaths by TB Status 
Table 3.1 below shows cohort patient distributions by some demographic 
factors, physical and health status/states. In the general population of the 
cohort 78% of the patients were between 26 to 45 years old ascertaining 
literature that shows this age group as one with the greatest incidence and 
 prevalence of HIV. This age interval was also noticed to be the interval 
accounting for the greatest number of deaths and default/loss to follow up.  
Many demographic variables on patients from the TLC cohort were not 
available for analysis. These variables such as residence, economic status, 
profession, religion and marital status were either very poorly collected or 
were not collected at all during regular patient visits for ARV collection or 
physical/ laboratory examinations. The TLC cohort patients presented as more 
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 of females (63.96%) than males (36.04%) with 95.68% of  
 
the patients considering them selves as blacks and less than 5% being either 
Asians, whites or coloureds. Amongst those who started treatment (ARV) 
between April 1
st
 2004 and April 1
st
 2007 at the TLC, 21.99% either defaulted 
or had a loss to follow up in that same 3years period of time. In the 78% that 
presumably continued treatment, a number of them died. The total number of  
Table 3.1: Numbers and proportions for some variables in the cohort 
No. Variable Category Frequency (%) 
18 – 25 265 4.55 
26 – 35 2,355 40.48 
36 – 45 2,193 37.69 
46 – 55 808 13.89 
1. Age group 
>55 197 3.39 
African (Black) 5,556 95.68 
Asian 14 0.24 
Coloured/Hispanic 213 3.67 
2. Ethnic Group 
White 24 0.41 
Male 2,097       36.04 3. Gender/Sex 
Female 3,721 63.96 
Non TB 4,770 81.99 4. TB State 
TB 1,048 18.01 
Before ARV start 346 5.95 
During ARV 632 10.86 
After 39 0.67 
5. Time of   occurrence TB  
Never had TB 4,770 81.99 
Loss to follow up 1,278 21.99 
Continuing treatment 4,264 73.38 
6. 
 
Treatment Status 
 
Dead 269 4.63 
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patients who died in the cohort amount 269 (4.63%)  
Considering those loss to follow up and deaths, we had 4264patients who 
were alive at the end of 1
st
 of April 2007. 
 
Table 3.2 above shows the distribution of various conditions and or states by 
patient record of TB. That is, if a patient ever presented with TB or not. 
The TLC cohort shows a greater proportion of the young adults developing 
TB in HIV than the aged. Those below 35years of age presented with no less 
than 18% of their population with TB at one point of their sero-positive state. 
Skeptically, we see that of all the deaths, only 19.33% were ever TB infected 
while 80.67% had never been infected. Males in this cohort seem to be more 
Table 3.2: Distribution of Demographic categories by TB status 
No. Variable Category Frequency (%) 
Non TB       %         TB         %     
18 – 25 213 80.38 52 19.62 
26 – 35 1,892 80.34 463 19.66 
36 – 45 1,801 82.12 392 17.88 
46 – 55 687 85.02 121 14.98 
1. Age group 
>55 177 89.85 20 10.15 
Black 4,556 82.00 1,000 18.00 
Asian 10 71.43 4 28.57 
Coloured 173 81.22 40 18.78 
2. Ethnic Group 
White 21 87.50 3 12.50 
Male 1,640 78.21 457 21.79 3. Gender/Sex 
Female 3,130 84.12 591 15.88 
Loss to follow up 1,031 80.67 247 19.33 
Continuing treatment 3,517 82.48 747 17.52 
4. 
 
Treatment Status 
 
Deaths 217 80.67 52 19.33 
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predisposed to developing TB as those who developed TB at one point in time 
make up 21.79% of the male population while for females; only 15.88% of 
them ever developed TB. The ethnic group with the highest proportion of TB 
by percentage is the Asians who had a total 28.57% of their general number 
presenting with TB. However the total number is small. They are followed by 
the coloureds and Africans with 18.78% and 18.00% of their total population 
respectively presenting with TB. For viral load which is not on the table, it 
was noticed that baseline observations showed that 88.83% of non TB patients 
had first viral loads below or equal to 400 while 11.17% presented with viral 
loads greater than 400. Amongst the TB patients, 89.34% of them had first 
viral load counts less than or equal to 400 and 10.66% of them presented with 
viral load counts greater than 400. 
As regards the summary of continues variables, the cohort noticed and 
compared means of several variables including BMI, age, CD4 counts, 
hemoglobin counts, weight, and the liver function tests of ALT and AST. 
Table 3.3 below, shows studentised t-test mean of some baseline outcome 
variables by patient’s TB status. From the table we notice that the mean of 
ALT one of the LFT in both groups of patients (TB and Non TB) stayed at 
clinically acceptable figures between 5 and 40. With the other LFT AST, 
figures are higher in both TB and non TB patients, and are significantly 
different in both groups. Differences in means among those who have ever 
been TB infected and those who have never had TB are also noticed when 
considering their various BMI. The figures of 22.58 and 20.76 for non TB and 
TB infected patients respectively could signify that those with TB either do 
 loss more weight than non TB patients by the onset of ART. 
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The same trend is noticed with weights of the two groups of patients where 
the baseline mean is higher in those who have never had TB than those who at 
a point in time have had TB. This trend also repeats it self with means of CD4 
and Hemoglobin counts which are higher in Non TB than in one time TB 
patients. The mean viral load (considered as a continuous variable) is higher 
in any time TB patients than those who never had TB, 171.23 and 165.90 
respectively. What is evident here is the fact that baseline mean viral load is 
far below 400. This is so because TLC has as protocol to check viral loads 
Table 3.3: Comparing means of first observations by TB Status-ttest distribution 
No. Variable TB Status Mean Std. dev ttest 95% CI Obs. p. value 
Non TB 22.58 4.83 22.42 - 22.75 3187 1. BMI 
TB 20.76 3.87 20.56 - 20.95 1462 
 
<0.0001 
Non TB 60.30 12.80 59.88 - 60.72 3538 2. Weight 
TB 55.97 10.60 55.44 - 56.50 1566 
 
<0.0001 
Non TB 113.47 104.68 107.41 - 119.52 1151 3. CD4 
TB 88.85 75.68 82.48 - 95.22 545 
 
<0.0001 
Non TB 11.90 2.34 11.15 - 11.42 1186 4. Hemoglobin 
TB 10.51 2.20 10.33 - 10.70 562 
 
<0.0001 
Non TB 4.48 1.09 4.41 - 4.55 913 5. Log Viral 
Load TB 4.50 1.11 4.39 - 4.60 469 
 
0.8237 
Non TB 31.34 33.80 29.43 - 33.25 1205 6. ALT 
TB 35.80 48.28 31.89 - 39.70 590 
 
<0.0001 
Non TB 44.19 42.05 41.82 - 46.57 1206 7. AST 
TB 55.18 50.58 51.09 - 59.27 589 
 
<0.0001 
Non TB 37.37  37.13 - 37.62 4770 8. AGE 
TB 36.20  35.72 - 36.68 1048 
 
<0.0001 
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only three months after the start of ARV and could prompt us to arguably say 
those who never develop TB do better when it comes to viral load decreasing. 
All these means also have some trends when we examine them by the time of  
Table 3.4: Distribution of change in outcome means by Months After Initiation of ARV 
Mean (Std. Dev) by Months of test post initiation on ARV No. Var. TB G. 
Baseline  3 6 9 12 
Non TB 103.23 
(102.58) 
+109.02 
(142.14) 
+117.80 
(125.05) 
+127.82 
(131.54) 
+179.60 
(140.60) 
1. CD4 
TB 78.35 
(71.91) 
+101.81 
(112.49) 
+142.29 
(131.34) 
+161.56 
(128.49) 
+179.55 
(136.67) 
Non TB  60.46 
(12.46) 
+0.98 
(13.15) 
+3.88 
(12.51) 
+4.99 
(12.75) 
+6.30 
(12.38) 
2. Weight 
TB 56.66 
( 11.05) 
+0.63 
(11.52) 
+3.92 
(11.54) 
+6.16 
(12.57) 
+7.99 
(12.68) 
Non TB 22.66 
(4.65) 
+0.41 
(4.92) 
+1.46 
(4.62) 
+1.92 
(4.98) 
+2.47 
(4.66) 
3. BMI 
TB 21.04 
(4.07) 
+0.25 
(4.31) 
+1.44 (4.16) +2.22 
(4.61) 
+3.05 
(4.67) 
Non TB 34.98 
(37.81) 
-3.87 
(25.25) 
-3.86 
(23.90) 
-4.91 
(21.30) 
-4.81 
(21.63) 
4. ALT 
TB 37.74 
(35.12) 
+3.84 
(41.32) 
-4.1 
(39.48) 
-8.26 
(22.38) 
-6.48 
(25.32) 
Non TB 48.21 
(58.90) 
-9.12 
(23.00) 
-9.99 
(24.95) 
-11.05 
(27.57) 
-11.53 
( 24.06) 
5. AST 
TB 56.98 
(44.02) 
-4.08 
(33.95) 
 -
14.77(23.69) 
-17.49 
(24.62) 
-17.51 
(30.32) 
Non TB 11.22 
(2.14) 
+0.55 
(2.19) 
+1.25 
( 2.06) 
+1.09 
(2.10) 
+1.74 
(2.02) 
6. Hb 
TB 10.30 
(2.13) 
+0.66 
(1.96) 
+1.99 
(1.98) 
+2.24 
(1.86) 
+2.59 
(2.38) 
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occurrence of TB (table 3.4). Figures and trends are shown in table 3.4 above. 
From table 3.4 above it should be noted that baseline for CD4 is considered as 
2months prior to and 1month after start of ARV. Other baselines values are 
taken within 1month of start of ARV. 
Figures 3.3, shows graphical distribution of weight among four groups of 
patients. Those who had TB and was cured before they started ARV (before), 
those who had TB and started ARV while still treating their TB (during), 
those who had TB long after they had started ARV medication (after) and 
lastly those who never had TB (never). 
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Fig.3.3 Distribution of weight by TB group 
The distribution of weight as seen in figure 3.3 looks to be fairly symmetrical. 
The same symmetry is seen in figure 3.4 where Hb distribution is shown by 
TB group. On the other hand, figure 3.13 (appendix) shows graphical 
distribution of CD4 counts and looks asymmetrical in the four groups. 
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Fig.3.4 Distribution of hemoglobin counts by TB group 
The distribution of weight and BMI over time also shows some clear signs of 
a trend (Table 3.4). These trends are better evident when looking at weight 
change over time among patients who have never presented with TB. The 
mean weight for this group moves from 60.46 at baseline to 61.44 in the third 
month of starting ARV, 64.34 by the sixth month, then 65.45 and 66.76 for 
the , 9
th
 and 12
th
 month of ARV initiation respectively. The trend of weight for 
those who have presented with TB follows same and increases over time. This 
is also true when BMI is considered were there is a constant increase in 
average BMI over time for both groups of patients. 
 
3.2 BIVARIABLE ANALYSIS 
Table 3.5 shows risk ratios of patients who had ever had TB (exposed) against 
those who have never had TB (unexposed). The risk among those who had TB 
of dying is 49.62deaths per 1000persons who have TB while that for those 
who never had TB is 45.49deaths per 1000persons without TB. This is also 
shown by some demographic factors sex, ethnic group, and age group. The 
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risk ratio is of two types, risk of dying (death) and the risk of defaulting/loss 
to follow up. 
 
Tables 3.6 below, shows bivariate risk ratio for patients, whether exposed or 
not, who default or are lost to follow up. Exposure is having TB at any point 
in time while those who never had TB are the unexposed. In both tables 
3.5and 3.6, there is no statistical evidence to say for sure that a particular 
group of persons or categories of persons have a higher risk of dying or 
defaulting as all confidence intervals contain 1. The only exception of this is 
noticed among those aged 18 – 25 where they show 1.51times more likely to 
default. Still the overall p value is far from significant. 
Table 3.5: Bivariate Analysis of TB status Risk Ratio of dying by Possible Confounders 
No. Variables Category RR of dying Confidence Interval P. value 
1. General  1.09        0.81 - 1.47 0.5647 
Female 1.13 0.76 - 1.69 2. Sex 
Male 1.00 0.64 - 1.56 
 
0.6860 
18 – 25 1.12 0.32 - 3.86 
26 – 35 1.38 0.87 - 2.19 
36 – 45 1.14 0.72 - 1.79 
46 – 55 0.50 0.16 - 1.61 
3. Age group 
>55 0.59 0.08 - 4.23 
 
 
0.5490 
Black/African 1.02 0.74 - 1.39 
Asian   _  
Coloured 1.57 0.53 - 4.68 
4. Ethnic 
group 
White   _  
 
 
0.4474 
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3.3 LEVELS AND DIFFERENTIALS (random effect linear regressions) 
To have an idea and make reasonable statistical inferences on different 
outcome variables relating to their changes over time after the start of ARV at 
the TLC, we plot regression models to evaluate this relationship between these 
variables by TB state or history of the patient. Table 3.7 shows coefficients, 
corresponding 95% confidence intervals and p. values for the relationship of 
various outcome variables with time. That is the trend of this outcome 
variables are studied to compare changes in the two groups of patients (TB 
and Non TB) over time (time after initiation of ARV and time is in Months). 
Table 3.6: Bivariate Analysis of TB RR for Loss to Follow up by Possible Confounders 
No. Variables Category RR Loss to follow up 95% CI P. value 
1. General  1.06 0.95 – 1.20 0.3051 
Female 1.08 0.92 – 1.26 2. Sex 
Male 1.01 0.85 – 1.20 
 
0.6009 
18 - 25 1.51 1.01 – 2.25 
26 - 35 1.15 0.97 – 1.36 
36 - 45 0.98 0.79 – 1.20 
46 - 55 0.82 0.55 – 1.21 
3. Age group 
>55 0.94 0.42 – 2.09 
 
 
0.1775 
Black/African 1.08 0.96 – 1.21 
Asian 0.83 0.12 – 5.82 
Coloured 0.91 0.48 – 1.70 
4. Ethnic 
group 
White 0.64 0.12 – 3.32 
 
 
0.8683 
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With all statistically significant coefficients, constants, and likelihood ratio 
statistic (likelihood ratio chi2- LR chi2), the progress of these outcome 
variables over the period post the start of ARV is shown to be slightly 
different among the two groups of patients- TB and non TB patients. The 
regression models plotted considered time in months after the start of ARV. 
Among patients who have ever been tested with TB, we could fit a model; 
yit = β0 + β1 periodstart + ui + eit       
Where “periodstart”, is number of months after the start of ARV therapy.  
Table 3.7: Regression Coefficients for relationship of Outcome variables with Time 
No. Variables TB group Constant                     Coefficients Conf. Interval P. value 
Non TB 23.12 0.06 0.06 - 0.07 < 0.001 1. BMI 
TB 21.53 0.11 0.10 - 0.11 < 0.001 
Non TB 61.63 0.17 0.16 - 0.18 < 0.001 2. Weight 
TB 57.96 0.30 0.28 - 0.31 < 0.001 
Non TB 194.25 7.56 7.22 - 7.91 < 0.001 3. CD4 
TB 186.92 6.92 6.46 - 7.37 < 0.001 
Non TB 12.22 0.04 0.035 - 0.045 < 0.001 4. Hb 
TB 11.88 0.06 0.05 - 0.07 < 0.001 
Non TB 31.96 -0.26 -0.33 - -0.19 < 0.001 5. ALT 
TB 33.98 -0.21 -0.32 - -0.10 < 0.001 
Non TB 41.15 -0.53 -0.61 - -0.45 < 0.001 6. AST 
TB 47.19 -0.64 -0.74 - -0.54 < 0.001 
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From this equation, we can see that with every unitary increase of periodstart 
that is every 1 additional month that passes sees average CD4 counts for non 
TB patients increasing by almost 7.56 while that of those who at a point in 
time have been TB positive have lower increases of 6.92 with every additional 
month that passes post ARV initiation. BMI, weight and hemoglobin averages 
are greater in non TB patients than in TB patients at start of ARV. In both 
groups the is a very slow increase as months go by but these increases are 
very slightly higher in any time TB patients than those who have never had 
TB. These is clear as coefficients are less than 1 and are always higher in TB 
patients for these variables. Also all coefficients, constants and LR chi2 are 
statistically significant with p. values < 0.05. 
The linear model that requested the maximum likelihood estimator also shows 
a decreasing number of liver function test counts with increasing months. 
With negative coefficients, AST decreases slightly faster in those who have 
had TB at some point than those who have never had TB. If their coefficients 
are fitted in the model equation that takes into account the structure of 
observations, the decrease is noticed to be slightly bigger in TB patients than 
non TB patients as the latter have bigger negative coefficients. The trend in 
ALT is a faster decrease among non TB patients than those who have ever had 
TB. Generally, we notice that ALT, Hemoglobin, weight and BMI start up 
with average mean values that are clinically acceptable for persons aged 18 
and above. With AST, those who have never had TB had as mean 41.15 
(when we fit 0 to the equation) at start of ARV which is clinically 
unacceptable (5 – 40). Also, those who had TB at some point before or after 
the start of ARVs had greater and clinically unacceptable means for AST. 
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3.4 SURVIVAL ANALYSIS  
Data was analysed using survival analysis in two ways. Analysis was done on 
demographics and the more binomial/categorical out come variables as death 
and ARV status. Survival analysis here was done as a simple one subject to 
one out come survival analysis; start time being the date when a patient started 
ARV medications at TLC and censored at April 01
st
 2007. An individual here 
had either survived or failed. In the second survival analysis, repeated data 
analysis was carried out. This involved longitudinally collected data and had 
as end points levels of CD4 count, viral load, hemoglobin counts, AST and 
ALT levels, weight and BMI changes and gains. Survival or failure is 
determined by the occurrence of an event adopted at levels determined for 
each variable. Since patients start ARV when the CD4 counts drops to < 200 a 
CD4 count greater than 200 was considered to be an event. For viral load the 
event was a viral load <400 (the lower limit of delectability in the assay used).  
For the test of liver function AST and ALT, failure occurs when an individual 
test scores above 40.. Failure with regard to hemoglobin occurs when an 
individual registers a negative change in hemoglobin. In regard to BMI and 
weight, failure and or success is achieved when an individual gains more than 
1 BMI point or gains more than 5% of weight respectively for the two 
variables. Even though these end points are positive results we use them as 
‘failures’ in the syntax of STATA survival analysis. Table 3.8 shows 
incidence rates per 100 patient years of the occurrence of the above ‘failure’ 
events while Table 3.9 shows RR obtained from multivariate models; Mantel-
Haenszel survival time/rates having controlled for sex, age group, ethnic 
group and time from start of AVR (startgorup). 
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The incidence rate of dead among those patients whom at one point after 
being sero-positive developed TB is at 3.84 deaths per 100 patient years while 
among those who never had TB its 4.16 deaths per 100 patient years giving a 
rate ratio of 0.93. This difference of a greater incidence of deaths among non 
TB patients is not statistically proven if we consider that the confidence 
interval of the rate ratio does includes 1. Regarding loss to follow up, that is 
whether an individual defaulted treatment or stopped coming for ARV, we 
notice that those who never had TB presented with higher incidence rates. 
They are 46% more likely to default than those who at one point have had TB 
(RR 0.54). The non TB patients have an incidence rate of 133.21 patients 
reaching CD4 counts greater than 200 per 100 patient years. This rate 
compares those who have had TB (124.88) with a rate ratio of 0.94 and CI 
Table 3.8: Incidence rate and ratio of failures in specified end point Variables 
No. Variables Inc. Rate Ratio Inc. RR 95% CI Inc. TB                  Inc. Non TB 
1. BMI 1.25 1.21 - 1.28 382.96 307.25 
2. Weight 1.40 1.35 - 1.45 291.25 208.08 
3. CD4 0.94 0.85 - 1.03 124.88 133.21 
4. Viral load 1.02 0.93 - 1.11 173.93 171.23 
5. Hb 0.77 0.63 - 0.94 24.54 31.70 
6. ALT 1.20 1.01 - 1.42 46.46 38.86 
7. AST 1.35 1.17 - 1.56 66.77 49.42 
8. Dead 0.93 0.66 - 1.28 3.84 4.16 
9. Loss to follow up 0.54 0.44 - 0.66 06.14 11.40 
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0.85 - 1.03. Looking at this rate and CI, we notice there is no real difference in 
changes of CD4 count between non TB patients and those who had TB. The 
same trend is noticed when comparing viral load between the two groups of 
patients where we notice that there is also no clear difference in patients 
reaching viral load test counts of 400 and below. The incidence rate of a 
patient having a positive gain in hemoglobin is statistically higher among non 
TB patients than those who had TB with a rate ratio of 0.77 comparing TB 
against non TB patients with CI 0.63 - 0.94. In the test for liver function, those 
patients who ever had TB presented with greater incidence of poor liver 
function (AST and ALT results of more than 40). In both AST and ALT 
results, rate ratio which are 1.35 and 1.20 respectively present with 
statistically significant CI which do not include 1. This shows that failure is 
higher when considering liver function test among TB patients than non TB 
patients. When it comes to body gains, it is noticed that TB patients seem to 
gain BMI more than non TB patients. The incidence of patients gaining more 
than 1unit of BMI is higher among TB patients than among non TB patients. 
This is the same trend noticed with weight where more onetime TB patients 
have higher incidences of more than 2kg gain of weight than non TB patients. 
 
In line with the incidences on table 3.8, survival and failure curves show 
graphically differences and similarities as seen. Figure 3.5, shows how there is 
a possible difference in deaths between TB and non TB patients. The survival 
curves for deaths in both HIV groups are close to each other. On checking for 
differences using Log Rank Test for equality of survival functions a p. value 
less than 0.0001 was obtained but a hazard function graph of the two patient 
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groups shows non parallel lines. This denies any assumption of similarity in 
the two groups with respect to incidence of deaths (Appendix B)  
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Fig.3.5 KM Survival curve for deaths by person days in cohort 
Figure 3.6, shows possible difference in out come of BMI between TB and 
non TB patients. It shows how fast every body gains more than 2kg in the 
cohort. Its failure curve at the appendix B shows the incidence of gaining 2kg 
in the cohort. 
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Fig.3.6 KM Survival curve in attaining +2kg in the cohort 
This difference in BMI in the two groups is statistically evident as a hazard 
function graph shows parallel lines for the two groups (figure 3.7) and log 
rank test presents with p.value 0.0001. Log rank test of equality of survival 
curves are for other outcome variables are shown in appendix B. 
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Fig. 3.7 Smooth hazard estimates of weight gain 
Where condition 1= Non TB and Condition 2= TB 
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Fig.3.8 Survival curve showing proportion of viral load <=400 
Figure 3.8 above shows how survival event which in this case shows almost 
every individual attaining viral load <=400 are reached by patient group TB 
and non TB. From the graph, no clear difference is noticed. This supported by 
the log rant test p value 0.83 which shows no significant difference in survival 
outcomes of attaining undetectable viral loads (<400) in the two patient 
groups. Failure curve for viral load shows proportion of patients attaining viral 
loads <=400 with person time (Appendix B.) 
Figure 3.9 below shows survival curve of loss to follow up. It gives the 
probability for an individual to still be in the cohort with time (days). 
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From the graph it is almost clear that loss to follow up is not similar in both 
groups of patients. In appendix B failure estimates, which is the probability of 
failing or of dropping out of the cohort are shown for the two patient groups 
with log rank test of equality of survival curves. The test shows a difference in 
the two groups with p.value < 0.0001 and a smoothed hazard curve with 
parallel lines. This probability does not consider those who died. 
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Fig.3.9 survival curve those who stayed in the cohort 
 
3.4 MULTIVARIATE SURVIVAL ANALYSIS 
In an attempt to explain the effects on the rate ratio of the study end points, 
models were fitted that take in to consideration sex, age group, ethnic group, 
and start group (month in which test or observation was done post ARV 
initiation). Table 3.9 below shows this multivariate analysis by the various 
survival end points. In this analysis having considered possible and available 
confounders as gender, age, ethnic group and interval from when a patient 
started ARV we noticed different outcomes. A negative confounding effect 
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was noticed of these confounders when we looked at the incidence rate ratio 
of deaths in the two groups of patients. In the multivariate analysis, the was no  
 
difference in the incidence of deaths among HIV TB patients and HIV non TB 
patients as they showed an RR CI including 1. This effect was also found to 
be non significant with p.value> 0.05. Among the defaulters (Loss to follow 
up), a statistically significant negative confounding effect was found. 
Controlling for age, sex, ethnic groups and time increased the RR to 0.76 
[p.value = 0.016]. This shows that though reduced, many more non TB 
patients defaulted than those who had TB at one point. The HIV patients 
without TB are 24% more likely to default. Difference in defaulting in the two 
groups of patients was also supported by parallel smoothed hazard curve lines 
and log rank test with p value < 0.0001. Negative confounding effects were 
Table 3.9: Multivariate survival analysis for RR of outcomes considering demographics 
No. Variables Rate Ratio RR 95% CI Chi2                  P. value 
1. BMI 1.29 1.25 - 1.32 301.31 < 0.001 
2. Weight 1.43 1.38 - 1.48 443.17 < 0.001 
3. CD4 0.96 0.87 - 1.06 0.74   0.391 
4. Viral load 1.00 0.91 - 1.10 0.00   0.990 
5. Hemoglobin 0.81 0.67 - 0.995 4.05   0.044 
6. ALT 1.17 0.98 - 1.39 3.17   0.075 
7. AST 1.36 1.17 - 1.57 16.42 < 0.001 
8. Dead 1.41 0.66 - 1.52 1.21   0.272 
9. Loss to follow up 0.76 0.60 - 0.95 5.80   0.016 
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also noticed in the out comes of AST, Hemoglobin, and BMI with all 
significant results. With AST and BMI, it was noticed that incidence of 
positive results was higher among TB patients while more non TB patients 
gained Hemoglobin values faster. A positive confounding effect was noticed 
when a model for weight outcome was done. Here it was more likely for non 
TB patients than TB patients to gain 2kg of body weight. Multivariate models 
for CD4, viral loads and ALT were not significant. 
Multivariate models that tried to control for baseline CD4 for the incidence of 
deaths and defaulting in the two groups of patients all proved to be 
statistically insignificant with RR of 2.15 [p.value = 0.114], CI 0.81 – 5.67 
when comparing defaulters in the two groups. 
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CHAPTER 4 
DISCUSSION 
The main objective of this study is to show differences in two different groups 
of HIV patients. That is those who had or have TB against those who have 
never had TB. The study compares these two groups of patients using 
statistical output comparisons of their summary statistics, regression models, 
survival and repeated data analysis models. Summary statistics shows 
numerical and proportional differences in the TB patients (that is those who at 
some point after being HIV positive were tested or diagnosed of TB) against 
non TB patients (those who have never had TB). The regression models fits 
changes in the outcome variables over time (months before and after the start 
of ARV). Survival and repeated data analysis shows incidences, rate ratio and 
survival, failures and hazard function curves. In an over view of the results, in 
most outcomes, there is no statistical evidence of a difference between the two 
groups of patients TB and non TB. In a few other outcomes like changes in 
BMI, weight, liver function and hemoglobin it is seen that those who at some 
stage had TB have a faster rate of improving on this outcomes. 
 
4.1 LIMITATIONS OF THE STUDY 
In view with the findings of this study, it is important that we acknowledge 
some limitations. These limitations are noticed to be of different sources. 
They could be results of errors and or practices at data collection phase, 
analysis, data entry, institutional rules and procedures and patients behaviour 
and honesty. 
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The positive outcome of very few deaths in the time period of the study which 
showed good reaction to ARV of the patients is in a way one of the analysis 
crisis. This is so because an analysis comparing death in the two groups of 
patients always certainly gives non-statistically significant results. 
Nonetheless, the sample of the study was quite exhaustive in number and in 
groups. 
Another limitation of the study is the issue of data collection and entry. Issues 
of dates entered wrongly as could be noticed in the dates of registration and 
start of ARV, dates not captured as in defaulters/loss to follow up, 
measurements which do not make mathematical sense (weights and heights 
captured as meters and centimeters in one variable, CD4, and LFT which do 
not reflect the tests) and observations which are not in sequence with 
presumable dates of event makes for poor statistical modeling and results. 
This aspect of the study causes it to be less as strong as it ought to be in 
bringing out differences and in it reliability. One thing to bear in mind though 
is the fact that cleaning of the TLC cohort is an ongoing activity – one day the 
will be a better cleaner dataset from the start. 
The absence of information for socio-economic status; wealth index, 
employment and or profession (which at onset of analysis was dropped due to 
proof of bias entries) which in literature is sure related to disease states, death, 
treatment adherence and efficacy makes certain important comparisons 
impossible to carry out. This problem is further compounded by the fact that 
data is secondary and the researcher cannot go back in time to modify any 
data collection tool or verify some of the responses/ observations. 
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Another limitation noticed is the fact that the study is unlikely to confidently 
compare outcomes taking into consideration ethnic groups alone as this 
variable is not at all representative of what is thought of the general public. 
The sample ethnic distribution is predominantly black with very few whites 
and coloureds. 
 
4.2 LEVELS AND DIFFERENTIALS 
4.2.1 Deaths 
There are very slight differences that are statistically proven in the study 
between TB and non TB patients. Such differences are seen in changes in 
weight, BMI, liver function (ALT and AST), hemoglobin and those who 
stopped (defaulted). Meanwhile, differences are not evident in deaths, CD4 
counts changes and viral load changes. This non statistical evidence of 
differences in deaths, CD4 and viral load is supported by a study carried out in 
Malawi on adults after initiation on ARV (16). The same non significance is 
observed when looking at deaths by various groups; sex, age group and ethnic 
group. Rate ratio of all groups and general model shows to have p value 
greater than 0.05. 
4.2.2 Stopped Treatment/Defaulters 
In contrast to the number of deaths, the number of those who stopped 
following up on their ARV medications or defaulted is not small and shows 
some statistical differences between the two groups of patients as shown by 
the rate of defaulting. This result is contrary to studies in Malawi (16) and 
Taiwan (12) which both found non-significant (p. values >0.05) differences in 
HIV TB patients and HIV non TB patients. Both studies concluded that there 
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were no differences in the drop out or defaulting rate in the two groups of 
patients. 
4.2.3 Viral Load 
Outcomes of viral load are not evident of any differences in the two groups of 
patients. At the first viral load test post ARV initiations; most of the patients 
had undetectable viral loads. This is so because viral loads are only checked 
for three months post start of ARV. In a continuous form, mean viral load are 
not significantly higher among TB patients than non TB patients. Survival 
analysis of the incidence of undetectable levels of viral load, we find that there 
are no differences in the two groups of patients in attaining undetectable viral 
loads as RR is approximately 1. This finding of no difference is supported by 
studies carried out in Taiwan (12), and Malawi (17) were in both cases 95% 
CI of RR contained 1 and p. values were greater than 0.05. Considering log 
viral loads we still notice that there is no difference in the two groups. 
4.2.4 Weight and BMI 
The cohort shows differences in mean values of weight and BMI at particular 
points in time significantly different between the two groups of patients TB 
and non TB. It is noticed that non TB patients generally have greater weights 
and BMI but the gradient of change with time is significantly higher with TB 
patients than non TB patients. This is supported by the survival and incidence 
rate at which patients gain 2kg of weight or 1unit of BMI which is higher in 
TB than in non TB patients. Basically it is biologically and physiologically 
correct for the mean values of weight and BMI at baseline to be higher in HIV 
non TB patients than in HIV TB patients and for this weight and BMI to 
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increase faster when in treatment for those who medically should have loose 
more the HIV TB patients.  
4.2.5 CD4 Counts 
Statistically there is no difference noticed in CD4 count change among the two 
groups of patients. In both cases though as clinically expected, there is a 
gradient of rising CD4 counts over time in ARV medication. Still, no true 
difference is evident in this rise of the CD4 over time in TB and non TB 
patients. These results of similarity in CD4 change in both groups of patients 
are in line with studies carried out in Malawi among children under 14years of 
age (17) and in Taiwan (12) that both show similar outcomes of CD4 counts in 
the two groups of patients.  
4.2.6 Hemoglobin Counts 
In a test of the means of baseline hemoglobin records for TB and non TB 
patients, it is noticed that there actually exist a difference among the two 
groups of patients at the onset of ARV. This difference is supported by 
regression analysis that shows changes with time in the two patient groups. In 
both cases, hemoglobin seems to increase with increasing time of receiving 
ARV. But the increase or change is not similar in both patient groups as those 
who at one point had TB even though start at baseline with lower hemoglobin 
(Hb) have a greater gradient in the rise of their hemoglobin with time. These 
findings are theoretically correct in that those who tend to be sicker had Hb 
levels dropping lower and so need to gain them faster to attain medically 
required states. Generally other studies of this nature rarely used Hb as one of 
the outcomes and so do not report on their differences in HIV TB patients 
against HIV TB-negative patients. 
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4.2.7 Liver Function Test- LFT (AST and ALT) 
Liver function test (LFT), which in this study is also used to compare 
differences in outcomes of HIV TB patients on ARV with HIV TB-negative 
patients also on ARV is not as direct in its interpretation as it can vary by 
gender, ethnicity, exercise and alcohol intake (43). In this study we notice that 
AST and ALT that are used to measure liver functioning here tend to decrease 
over time. High figures usually above 40 indicate poor function and possible 
cirrhosis and or tissue damage. The decrease with time of AST and ALT is 
noticed in both patient groups. But the incidence of values over 40 for AST 
and ALT is higher among TB patients than those who have never had TB in 
univariate models. When we take into considerations other demographic 
characters (gender, ethnic group, age) we notice that there are no clear 
differences in ALT outcomes in both groups even though AST values 
statistically differ in the two groups of patients. Also noticed with changes 
over time is the faster decrease among non TB patients of both AST and ALT. 
To note is the fact that difference in AST above could be more due to another 
embedding disease than to TB as other studies like one carried out in Italy 
have shown no significant difference in liver function test between a range of 
different groups of patients (44). 
4.3 Predictors of failures or successes in Outcome variables 
In an attempt to view effects of confounders and determine other predictors 
for outcome results, we find out that all of our available demographic factors 
were not significant confounders to outcomes in HIV TB and HIV non TB 
patients. They were not as a group characteristics related to differences 
between the two groups of patients. An exception of this could be suspected 
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with ALT out comes which proves not significant at multivariate models even 
though significant at univariate level. 
With the absence of important demographic information like profession, 
income, and general socio-economic class much is believed to have been left 
out as concerns possible predictors. Outcomes of CD4, Hb, weight/BMI and 
others are expected to have a relationship with nutrition, standard of living 
and daily physical activities. 
Overall, a factor which almost certainly blunted the differences between TB 
and non-TB patients, as defined in this study, was that the TB group contained 
all patients who had ever been exposed to the condition. Thus the TB group 
included patients who had had TB and who had completed TB treatment prior 
to presenting with AIDS, some in whom TB was part of an AIDS defining 
condition but had completed TB treatment prior to ARV, some who were on 
overlapping HAART and anti-tuberculous therapy for varying periods and 
some who had developed TB after starting ARV/HAART, either as part of the 
Immune Reconstitution Inflammatory Syndrome (IRIS-TB) or as incident TB.  
These different groups are an important source of bias in the present study and 
will obviously have to be taken into account in a more detailed analysis than 
was appropriate here.  Never-the-less, the findings that the groups, as defined 
in this study, differed is of interest as a first step towards further analysis.  
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CHAPTER FIVE 
 
CONCLUSION AND RECOMMENDATIONS 
 
5.1 CONCLUSION 
 
This study was designed to evaluate and compare differences in outcomes 
among HIV patients who have been diagnosed with TB against those HIV 
patients who have never had TB. Results from summary statistics, regressions 
student t-test, chi-squared test survival and repeated data analysis show 
generally fewer than thought of differences. An important reason for this 
maybe the inhomogeneous nature of the TB group. Slight significant 
differences were noticed in the weights and BMI of the two groups of patients 
where those without TB tended to have greater weights/BMI than those who 
had TB. But here too it was noticed that the gradient of increase of weight and 
BMI are very slightly greater in those with baseline lower weights/BMI (those 
who had TB) than those whose weight and BMI were already high. In the 
same way was small statistically evident differences noticed with outcomes of 
Hb, and AST. 
The lack of association between the social/demographic factors and ARV 
outcomes can be associated with the fact that individuals of all gender, race, 
social class and age are becoming more and more aware of the problems and 
challenges of HIV and TB and by so take better care of themselves while 
striving to achieve better health. Also the fact that the burden of such 
conditions have been seen to be of so much disadvantage to states/countries 
that treatment have become virtually free in both diseases in most countries. 
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5.2 RECOMMENDATIONS 
With the difficulties obtained in managing and reporting data, information 
from TLC can be priceless if data capture and entry were to be improved 
upon. Nonetheless, with the major outcomes of ARV (CD4 and viral load),  
not significantly different in both groups of patients and both groups 
experiencing significant improvements in their health states, it is all but 
normal to propagate for a wider coverage of HIV infected individuals with 
prompt initiation to ARV. 
The fact that some important data was missing like occupation and socio-
economics factors due to respondent fear of their effects on their treatment 
cost should serve as a boost to provide cheap, equal and passionate care to all 
persons no matter their social class. This could help in improving research 
findings and assumptions. 
The South African government guidelines do not include base-line viral load 
measurements and the first viral loads are usually collected four to six months 
post ART initiation. This makes it difficult, in all but a few cases, to assess the 
rate of viral load decline as most of the patients would have attained 
undetectable viral loads before their first test post ARV initiation. 
Further analysis of the TLCC data is needed where the timing of the diagnosis 
of TB with respect to the diagnosis of AIDS and the initiation of both TB 
treatment and HAART are taken into account. 
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APPENDIX B 
Graphs of Summary and Survival statistics including Log rank test of equality 
of survival curves 
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Fig.3.10 Distribution of CD4 counts by TB groups 
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Fig.3.11 Structural distribution of Age 
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Graphs and information on deaths 
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Smooth hazard curve of those who died in the cohort 
Log-rank test for equality of survivor functions 
 
          |   Events         Events 
condition |  observed       expected 
----------+------------------------- 
NON TB    |        48          32.85 
TB        |       139         154.15 
----------+------------------------- 
Total     |       187         187.00 
                chi2(1) =       8.51 
                Pr>chi2 =     0.0035 
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Fig.3.12 KM Incidence of deaths by person days in the cohort 
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Graph and information on Weight 
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Fig. 3.13 Failures showing incidence of patients gaining >=2kg weight 
Log-rank test for equality of survivor functions 
          |   Events         Events 
condition |  observed       expected 
----------+------------------------- 
NON TB    |     13505       12939.37 
TB        |      7123        7688.63 
----------+------------------------- 
Total     |     20628       20628.00 
                chi2(1) =      69.23   Pr>chi2 =     0.0000  
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Graph and information on Viral Load 
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Fig.3.14 survival curve showing proportion not attaining viral load 
<=400 
Log-rank test for equality of survivor functions 
 
          |   Events         Events 
condition |  observed       expected 
----------+------------------------- 
NON TB    |      1185        1189.46 
TB        |       757         752.54 
----------+------------------------- 
Total     |      1942        1942.00 
 
                chi2(1) =       0.04    Pr>chi2 =     0.8345 
 
 
Graph and information on Loss to follow up 
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KM survival curve of loss to follow up 
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Smoothed Hazard curve for loss to follow up 
Log-rank test for equality of survivor functions 
 
          |   Events         Events 
condition |  observed       expected 
----------+------------------------- 
NON TB    |       141          89.28 
TB        |       374         425.72 
----------+------------------------- 
Total     |       515         515.00 
                chi2(1) =      36.43 
                Pr>chi2 =     0.0000 
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
0 500 1000
analysis time
condition = NON TB condition = TB
Kaplan-Meier failure estimates, by condition
 
Failure curve showing percentage loss to follow up 
Graphs and information on BMI 
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KM Survival curve of gaining 1 and more BMI units 
Bmi Log-rank test for equality of survivor functions 
          |   Events         Events 
condition |  observed       expected 
----------+------------------------- 
NON TB    |     11281       12333.13 
TB        |      8643        7590.87 
----------+------------------------- 
Total     |     19924       19924.00 
                chi2(1) =     240.50    Pr>chi2 =     0.0000 
.0
0
4
.0
0
6
.0
0
8
.0
1
.0
1
2
0 200 400 600 800 1000
analysis time
condition = 1 condition = 2
Smoothed hazard estimates, by condition
 
Hazard estimates by condition for BMI 
Graphs and information on Hemoglobin 
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KM Survival curve for positive change of hemoglobin                    
Log-rank test for equality of survivor functions 
          |   Events         Events 
condition |  observed       expected 
----------+------------------------- 
NON TB    |       299         274.90 
TB        |       149         173.10 
----------+------------------------- 
Total     |       448         448.00 
                chi2(1) =       5.50  Pr>chi2 =     0.0191 
0
.0
0
1
.0
0
2
.0
0
3
0 200 400 600 800 1000
analysis time
condition = 1 condition = 2
Smoothed hazard estimates, by condition
 
Hazard function curve of failing by having positive Hb gains 
Graphs and information on AST 
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KM survival curve of developing negative AST scores (>40) 
Log-rank test for equality of survivor functions 
          |   Events         Events 
condition |  observed       expected 
----------+------------------------- 
NON TB    |       411         468.63 
TB        |       349         291.37 
----------+------------------------- 
Total     |       760         760.00 
                chi2(1) =      18.60    Pr>chi2 =     0.0000 
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Hazard estimates by condition for AST 
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Graphs and information on ALT 
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Survival curve for those who do not develop ALT scores >40 
Log-rank test for equality of survivor functions 
          |   Events         Events 
condition |  observed       expected 
----------+------------------------- 
NON TB    |       329         354.49 
TB        |       244         218.51 
----------+------------------------- 
Total     |       573         573.00 
                chi2(1) =       4.83  Pr>chi2 =     0.0279 
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Hazard estimates by condition for ALT 
Graphs and Information on Viral load 
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Survival curve for those who develope viral load less than 400 
Log-rank test for equality of survivor functions 
          |   Events         Events 
condition |  observed       expected 
----------+------------------------- 
NON TB    |      1185        1189.46 
TB        |       757         752.54 
----------+------------------------- 
Total     |      1942        1942.00 
                chi2(1) =       0.04 Pr>chi2 =0.8345 
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Harzard estimates for failing by attaining viral load <=400 
(undetectable) 
Graphs and information for CD4 counts 
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Survival curve showing probability of not developing CD4 over 200 
Log-rank test for equality of survivor functions (CD4) 
          |   Events         Events 
condition |  observed       expected 
----------+------------------------- 
NON TB    |      1235        1195.88 
TB        |       706         745.12 
----------+------------------------- 
Total     |      1941        1941.00 
                chi2(1) =       3.36  Pr>chi2 =     0.0666 
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Hazard estimates of failing by developing CD4 above 200 
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APPENDIX C 
Plan of Movement on patient arrival at the Themba Lethu Clinic 
 
